Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026)
Soleno Therapeutics' (SLNO) quarterly Return on Capital Employed came in at 14.75% in Q1 2026, up 8274.0% year-on-year from 0.18% in Q1 2025, and up 715.65% on a QoQ basis from 1.81% in Q4 2025.
Soleno Therapeutics (SLNO) Return on Capital Employed (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 13 years of Return on Capital Employed data on file, last reported at 14.75% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 8274.0% year-over-year to 14.75% in Q1 2026; TTM through Mar 2026 was 14.75%, a 8274.0% increase from a year earlier, with the FY2025 full-year figure at 2.44%, up 8160.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 14.75%, up from 1.81% in the prior quarter.
- Over the last five years, Return on Capital Employed for SLNO reached as high as 14.75% in Q1 2026 and fell as low as 181.25% in Q3 2023.
- Historically, Return on Capital Employed has averaged 73.03% across 5 years, with a median of 63.6% in 2024.
- Across the five-year window, Return on Capital Employed sank 10255 bps in 2023 and jumped 14405 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 111.27% in 2022, then surged by 66 bps to 37.41% in 2023, then sank by 70 bps to 63.6% in 2024, then soared by 103 bps to 1.81% in 2025, then surged by 716 bps to 14.75% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 14.75% in Q1 2026, 1.81% in Q4 2025, and 20.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn | 14.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.75% |
| Dec 31, 2025 | 1.81% |
| Sep 30, 2025 | -20.63% |
| Jun 30, 2025 | -62.97% |
| Mar 31, 2025 | -67.99% |
| Dec 31, 2024 | -63.60% |
| Sep 30, 2024 | -49.91% |
| Jun 30, 2024 | -31.95% |
| Mar 31, 2024 | -34.96% |
| Dec 31, 2023 | -37.41% |
| Sep 30, 2023 | -181.25% |
| Jun 30, 2023 | -176.00% |
| Mar 31, 2023 | -177.60% |
| Dec 31, 2022 | -111.27% |
| Sep 30, 2022 | -80.46% |
| Jun 30, 2022 | -73.45% |
| Mar 31, 2022 | -88.68% |
| Dec 31, 2021 | -101.53% |
| Sep 30, 2021 | -99.60% |
| Jun 30, 2021 | -81.24% |